Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $64.5 million.

  • IDEAYA Biosciences' Total Current Liabilities rose 5865.86% to $64.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.5 million, marking a year-over-year increase of 5865.86%. This contributed to the annual value of $46.1 million for FY2024, which is 6999.74% up from last year.
  • As of Q3 2025, IDEAYA Biosciences' Total Current Liabilities stood at $64.5 million, which was up 5865.86% from $55.3 million recorded in Q2 2025.
  • Over the past 5 years, IDEAYA Biosciences' Total Current Liabilities peaked at $64.5 million during Q3 2025, and registered a low of $24.9 million during Q3 2023.
  • Its 5-year average for Total Current Liabilities is $40.3 million, with a median of $38.6 million in 2021.
  • As far as peak fluctuations go, IDEAYA Biosciences' Total Current Liabilities soared by 39181.87% in 2021, and later crashed by 5638.24% in 2023.
  • IDEAYA Biosciences' Total Current Liabilities (Quarter) stood at $45.2 million in 2021, then fell by 29.76% to $31.7 million in 2022, then dropped by 14.56% to $27.1 million in 2023, then surged by 70.0% to $46.1 million in 2024, then soared by 40.02% to $64.5 million in 2025.
  • Its Total Current Liabilities stands at $64.5 million for Q3 2025, versus $55.3 million for Q2 2025 and $50.8 million for Q1 2025.